Asset Details
Do you wish to reserve the book?
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
Do you wish to request the book?
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
2013
Overview
In acutely ill patients, 10 days of rivaroxaban was noninferior to 10 days of enoxaparin for thromboprophylaxis. Extended-duration rivaroxaban treatment (35 days) reduced the risk of venous thromboembolism. Rivaroxaban was associated with an increased risk of bleeding.
Patients with active cancer, stroke, myocardial infarction, or acute exacerbations of a variety of medical conditions are at increased risk for venous thromboembolism.
1
Prolonged immobilization and risk factors such as an age older than 75 years, chronic heart failure, a history of venous thromboembolism, and obesity can increase this risk further.
2
,
3
Randomized, controlled trials involving hospitalized patients at increased risk for venous thromboembolism have shown the benefits of administering anticoagulant agents for up to 14 days,
4
–
8
and guidelines recommend the use of unfractionated heparin, low-molecular-weight heparins, or fondaparinux in such patients.
9
There is some evidence that the risk . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Anticoagulants - adverse effects
/ Anticoagulants - therapeutic use
/ Biological and medical sciences
/ Drug Administration Schedule
/ Enoxaparin - adverse effects
/ Enoxaparin - therapeutic use
/ Female
/ Hemorrhage - chemically induced
/ Humans
/ Male
/ Morpholines - adverse effects
/ Morpholines - therapeutic use
/ Public health. Hygiene-occupational medicine
/ Thiophenes - adverse effects
/ Thiophenes - therapeutic use
